背景:由于最突出的疫苗的III期试验排除了免疫受损或免疫抑制的患者,关于SARS-CoV-2疫苗用于实体器官移植受者的安全性和有效性的数据很少.
目的:我们的研究提供了与现有数据相一致的专家意见的综合,以解决移植患者SARS-CoV-2疫苗临床管理的关键问题。
方法:进行了一项在线研究,检索了国家和国际移植组织以及国家机构对移植受者的SARS-CoV2疫苗接种管理的可用建议。
结果:从18个国家和国际协会的建议中确定了11个关键声明,并通过社会建议共识评分评估个人陈述的共识。尽管预期免疫反应减弱,但发现移植患者优先接种疫苗的最高共识水平(SRCA)。所有目前授权的疫苗对移植患者(SRCA)都是安全的。免疫抑制药物的处理,及时管理疫苗,和其他方面与现有的专家意见一致。
结论:专家共识可以确定实施SARS-CoV-2疫苗接种计划的关键方面。在获得经验数据之前,我们特此提供即时决策的工具。
BACKGROUND: Since phase III trials for the most prominent vaccines excluded immunocompromised or immunosuppressed patients, data on safety and efficacy of SARS-CoV-2 vaccines for recipients of solid organ transplantations are scarce.
OBJECTIVE: Our study offers a synthesis of expert opinions aligned with available data addressing key questions of the clinical management of SARS-CoV-2 vaccinations for transplant patients.
METHODS: An online research was performed retrieving available recommendations by national and international transplantation organizations and state institutions on SARS-CoV2 vaccination management for transplant recipients.
RESULTS: Eleven key statements were identified from recommendations by 18 national and international societies, and
consensus for the individual statements was evaluated by means of the Society Recommendation
Consensus score. The highest
consensus level (SRC A) was found for prioritized access to vaccination for transplant patients despite anticipation of a weakened immune response. All currently authorized vaccines can be considered safe for transplant patients (SRC A). The handling of immunosuppressive medication, the timely management of vaccines, and other aspects were aligned with available expert opinions.
CONCLUSIONS: Expert
consensus can be determined for crucial aspects of the implementation of SARS-CoV-2 vaccination programs. We hereby offer a tool for immediate decision-making until empirical data becomes available.